Piper Jaffray Downgrades XOMA, Ltd. (XOMA) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Jefferies Downgrades XOMA, Ltd. (XOMA) to Hold
July 23, 2015 7:23 AM EDTJefferies downgraded XOMA, Ltd. (NASDAQ: XOMA) from Buy to Hold with a price target of $1.00 (from $7.00).
Analyst Biren Amin commented, "XOMA announced that gevokizumab missed on the primary endpoint on time to first exacerbation in EYEGUARD-B for Behcets uveitis as a result of... More
Ladenburg Thalmann Downgrades XOMA, Ltd. (XOMA) to Neutral
July 22, 2015 2:32 PM EDTLadenburg Thalmann downgraded XOMA, Ltd. (NASDAQ: XOMA) from Buy to Neutral with a price target of $1.00 (from $6.00).
For an analyst ratings summary and ratings history on XOMA, Ltd. click here. For more ratings news on XOMA, Ltd. click here.
Shares of XOMA, Ltd. closed at $4.40 yesterday.
... MoreRBC Capital Downgrades XOMA, Ltd. (XOMA) to Sector Perform
July 22, 2015 1:38 PM EDTRBC Capital downgraded XOMA, Ltd. (NASDAQ: XOMA) from Outperform to Sector Perform with a price target of $2.00 (from $8.00).
Analyst Adnan Butt said, "Phase III Behcets study was higher risk but going forward is likely to create uncertainty around Phase III... More
Cowen Downgrades XOMA, Ltd. (XOMA) to Market Perform
July 22, 2015 12:57 PM EDTCowen downgraded XOMA, Ltd. (NASDAQ: XOMA) from Outperform to Market Perform after the company announced that gevo's EYEGUARD-B trial in Behçets uveitis did not meet its primary endpoint. The firm said the gevo's viability is now in question.
Analsyt Phil Nadeau... More
It's NOT 'Game Over' for XOMA (XOMA), Wedbush Says; PT to $13
July 22, 2015 12:55 PM EDTWedbush analyst Liana Moussatos cut here price target on XOMA, Ltd. (NASDAQ: XOMA) to $13.00 (from $17.00) after Gevokizumab failed to meet the primary endpoint in its Phase 3 EYEGUARDB trial in patients with Behçets disease uveitis (BDU). However, the firm maintained its Outperform rating saying it is... More
XOMA (XOMA) Slammed 70% as Trading Resumes
July 22, 2015 8:33 AM EDTXOMA (NASDAQ: XOMA) has resumed trading and is down 67% after announcing the Phase 3 EYEGUARD-B study of gevokizumab in patients with Bechet's disease uveitis, run by its partner Servier, did not meet the primary endpoint of time to first acute ocular exacerbation.
... MoreXOMA (XOMA) to Resume Trading at 8:30 AM
July 22, 2015 8:03 AM EDTXOMA (NASDAQ: XOMA) to Resume Trading at 8:30 AM
... MoreXOMA (XOMA) Announced Phase 3 EYEGUARD-B Missed Primary Objective
July 22, 2015 8:01 AM EDTXOMA (NASDAQ: XOMA) announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet's disease uveitis, run by its partner Servier, an independent French pharmaceutical research company driven by the pursuit of innovative drugs, did not meet the primary endpoint of time to first acute ocular exacerbation.
"Although the study did not achieve its main objective, we did see signals of drug activity such as preserved visual acuity, less severe ocular exacerbations... More
XOMA (XOMA) halted with news pending
July 22, 2015 7:57 AM EDTXOMA (NASDAQ: XOMA) halted with news pending.
... More